JRJoel Rosenblatt

Joel Rosenblatt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joel Rosenblatt has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Issam Raad

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

    14 shared publications
  • Bahgat Gerges

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center

    11 shared publications
  • Y Lan Truong

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center

    8 shared publications
  • Issam Raad

    Department of Infectious Diseases, Infection Control and Employee Health, University of Texas M.D. Anderson Cancer Center, Unit 1460, Houston, TX 77030, USA

    7 shared publications
  • Ray Hachem

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

    7 shared publications
  • Ruth A. Reitzel

    Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    7 shared publications

Latest Publications

  • Open Access

    Antimicrobial elution patterns correlate with antibacterial and antifungal activities of three antimicrobial central venous catheters in serum

    by Issam I. Raad, Y-Lan Truong, Bahgat Gerges, Ying Jiang, Ray Hachem, Peter Lamie, Anne-Marie Chaftari, Joel Rosenblatt

    Antimicrobial central venous catheters (CVCs) help prevent CVC-related bloodstream infection (CRBSI), and their effectiveness depends on sustaining broad antimicrobial activity in serum. A new CVC containing minocycline, rifampin, and chlorhexidine (MRC) was recently approved, complementing existing minocycline-rifampin (MR) and chlorhexidine-silver-sulfadiazine (CSiSz) CVCs. This study compared the elution profiles of minocycline, rifampin, and chlorhexidine from these three CVC types in serum and assessed resulting antimicrobial durability against CRBSI pathogens. MRCs were prepared by impregnation with minocycline and rifampin, followed by sequential chlorhexidine coating; commercial MR and CSiSz CVCs served as comparators. CVCs were immersed in plasma for 24 h, and then in serum for 3 weeks. At baseline and weekly intervals, CVC segments were analyzed for antimicrobial content and challenged with clinical CRBSI isolates. MRC retained higher minocycline and rifampin levels than MR and higher chlorhexidine levels than CSiSz after 3 weeks in serum. Correspondingly, MRC demonstrated superior inhibition of gram-negative colonization ( Klebsiella pneumoniae , Escherichia coli , Acinetobacter baumannii ) and Enterococcus faecalis at week 3 ( P ≤ 0.028). They also showed greater activity against Candida species (spp.) ( C. albicans , C. glabrata ) at weeks 2 and 3 ( P ≤ 0.005). MR and MRC CVCs completely prevented methicillin-resistant Staphylococcus aureus and S. epidermidis colonization for 3 weeks, outperforming CSiSz ( P = 0.003). In conclusion, slow elution from MRC CVCs resulted in significantly enhanced antimicrobial durability against gram-negative bacteria, E. faecalis , and Candida spp. MR and MRC CVCs provided equivalent, sustained protection against Staphylococcal colonization, both surpassing CSiSz CVCs.


  • Open Access

    Elevated Antibacterial Activity of a Polygalacturonic + Caprylic Acids Wound Ointment Compared with Hypochlorous Acid in a Three-Dimensional Wound Biofilm Model

    by Bahgat Gerges, Joel Rosenblatt, Y-Lan Truong, Ying Jiang, Issam Raad

    Bacterial biofilms play a major role in delayed wound-healing and in the development of chronic, non-healing wounds. Natural, plant-based agents, which can eradicate bacterial biofilms, are alternatives to antibiotics and antiseptics in the treatment of bacterially contaminated wounds. Bacterial wound biofilms are three-dimensional and complex microbial communities. Therefore, in this study, we used a three-dimensional fibrin-gel wound biofilm (FGWB) model to compare a commonly used natural agent in wound care, hypochlorous acid (HOCl), to a combination of two natural plant-based agents, polygalacturonic acid (PG) and caprylic acid (CAP) (PG + CAP), for their abilities to eradicate resistant bacterial biofilms of common wound pathogens methicillin resistant Staphylococcus aureus (MRSA), multi-drug resistant (MDR) Pseudomonas aeruginosa, metallo β-Lactamase Escherichia coli, and Streptococcus pyogenes. PG + CAP produced a significantly greater reduction in viable organisms when compared to HOCL (p ≤ 0.05) against all tested bacterial isolates. PG + CAP was highly effective against biofilms of all resistant bacterial isolates and is a promising option that merits further study for treating chronic wounds contaminated with bacterial biofilms.

  • Open Access

    A Prospective Randomised Clinical Study Comparing Polygalacturonic and Caprylic Acid Ointment to Medical‐Grade Honey in the Management of Chronic Wounds

    by Hiba Dagher, Ray Y. Hachem, Christopher Hakim, Rola Husni, Diya' S. Hammoudeh, Mira Bou Karroum, Nelson Hamerschlak, Fernanda Ferraz Assir, Janane Nasr, Joel Rosenblatt, et al.

    The aim in this human trial is to compare the efficacy and safety of polygalacturonic–caprylic acid (PG–CAP) ointment to MediHoney in chronic wounds at three international medical centres. In this prospective open‐label study, patients with chronic full‐thickness wounds were randomised to daily treatment with PG–CAP ointment or MediHoney. Assessments were obtained weekly for 6 weeks. The validated Pressure Ulcer Scale for Healing (PUSH) score was used to track healing. Efficacies were compared using the Wilcoxon rank‐sum test for continuous variables and chi‐square or Fisher's exact test for categorical variables. Twenty‐six patients with chronic wounds were included. Baseline characteristics were comparable between the groups; however, the history of diabetes mellitus was higher in the PG–CAP group ( p = 0.011). All 13 PG–CAP patients showed improvement (100%), compared to only 69% of the 13 MediHoney patients ( p = 0.023). Half of the failures in the MediHoney arm were associated with death (15%). No failures, adverse events or deaths occurred in the PG–CAP arm. PG–CAP wound ointment is a novel combination of two plant‐based compounds that pose minimal risk of promoting antimicrobial resistance, was highly effective for eradicating wound‐pathogen biofilms in vitro and promoted chronic wound healing in vivo with minimal inflammatory reactions. Our findings support PG–CAP as safe, noninferior and possibly more effective than MediHoney in healing chronic contaminated wounds.


  • Open Access

    Elevated Antibacterial Activity with Decreased Cytotoxicity of a Polygalacturonic + Caprylic Acid Wound Ointment Compared with Hypochlorous Acid in a Three-Dimensional Wound Biofilm Model

    by Bahgat Gerges, Joel Rosenblatt, Y-Lan Truong, Ying Jiang, Issam Raad

    Introduction: Natural, plant-based agents are alternatives to antibiotics and antiseptics in treating bacterially colonized wounds and potentially offer an antimicrobial activity without cytotoxicity. In this study, we used a three-dimensional fibrin-gel wound biofilm (FGWB) model to be more representative of the wound biofilm environment. We compared a common antiseptic wound care agent, hypochlorous acid (HOCl), with a combination of two plant-based agents; polygalacturonic acid (PG) and caprylic acid (CAP) for bacterial biofilm eradication and assessed their cytotoxicities towards fibroblast cells. Material and Methods: The efficacy PG+CAP ointment was compared to HOCl irrigant solution in biofilm eradication using the FGWB against clinical resistant bacterial isolates of MRSA, MDR Pseudomonas aeruginosa, CRE Escherichia coli, and Streptococcus pyogenes. Trypan blue exclusion and Alamar blue conversion assays were used for cytotoxicity assays. Results: PG+CAP produced a significantly greater reduction of viable organisms than HOCl for all tested bacterial isolates in the FGWB model (P≤ 0.05). Also, cytotoxicity tests showed that, PG+CAP was comparable to the non-antimicrobial negative control and was less cytotoxic than HOCl (P≤0.05). Conclusion: PG+CAP was highly effective against biofilms of highly resistant bacterial isolates in the FGWB model, and less cytotoxic than HOCl. PG+CAP merits further in vivo study.

  • Open Access

    The Antifungal Activity of a Polygalacturonic and Caprylic Acid Ointment in an In Vitro, Three-Dimensional Wound Biofilm Model

    by Bahgat Z. Gerges, Joel Rosenblatt, Y-Lan Truong, Ying Jiang, Issam I. Raad

    Candida colonization and biofilms are significant contributors to impaired wound healing. Consequently, improved treatments are needed to eradicate Candida biofilms in wounds. Wounds present complex biofilm extracellular matrix environments, with microbial cells frequently enmeshed in matrices comprising wound exudate macromolecular gels. We evaluated the ability of a polygalacturonic and caprylic acid (PG + CAP) ointment to eradicate Candida albicans, C. parapsilosis, C. glabrata, C. tropicalis, and C. auris biofilms in a fibrin gel wound biofilm model of the complex wound biofilm environment. Hypochlorous acid (HOCl) is a disinfecting antimicrobial agent that is widely used as wound irrigant, and this was used as a comparator. A single treatment with PG + CAP reduced the number of viable organisms in the C. albicans and C. glabrata biofilms by over 5 log10, in the C. parapsilosis and C. auris biofilms by over 4 log10, and in the C. tropicalis biofilm by 3.85 log10. PG + CAP was superior (p < 0.01) to HOCl in eradicating all Candida species biofilms, except for C. auris, for which both treatments fully eradicated all viable organisms. The use of HOCl in Candida-colonized wounds should include consideration of the extracellular matrix load in the wound bed. PG + CAP warrants further study in wounds compromised by Candida biofilms.


  • Open Access

    2123. Novel Antimicrobial Polycarbonate Coating for Intravenous Connectors

    by Y Lan Truong, Bahgat Z Gerges, Joel Rosenblatt, Issam I Raad

    IV connectors are ubiquitous access junctions in vascular access circuits. Unlike vascular catheters and IV lines made from soft polymers, connectors are made from rigid polycarbonate (PC) to prevent deformation during manipulation. In accessing PC connectors (PCCs) for infusion, PCCs are vulnerable to becoming microbially contaminated. Here we report development of a novel antimicrobial polycarbonate coating for preventing microbial colonization of IV connectors. The FDA recently approved a new antimicrobial polyurethane catheter coating that comprised Minocycline (M), Rifampin (R), and Chlorhexidine (C). We spray-coated MRC onto PCCs as sequential laminate layers of M, R and C in PC or blend PC and polycarbonate-urethane copolymers. MRC coated PCCs were immersed in tubes filled with 50% serum + 50% saline to simulate elution of the coatings. After 7 days (typical interval of use prior to replacement of IV connectors), eluted connectors were exposed to challenge inocula of key CLABSI pathogen clinical isolates for 24 hours and the number of colonizing microbes were enumerated by sonication, serial dilution, plating and colony counting. Non-coated PCCs were positive controls. The absence of microbial colonization of the MRC IV connectors demonstrates the efficacy and durability of the novel MRC polycarbonate laminate coating. MRC coated connectors merit further testing in vitro and in vivo for their potential to prevent CLABSI. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License

  • Open Access

    2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer

    by Bahgat Z Gerges, Y Lan Truong, Joel Rosenblatt, Ray Y Hachem, Anne-Marie Chaftari, Samuel A Shelburne, Issam I Raad

    Gram negative (GN) bacterial infections are on the rise in patients with cancer (PWC). There is an urgent need for new therapies to address the rise of infections caused by multidrug resistant (MDR) GN pathogens. Taniborbactam is a β-lactamase inhibitor in combination with cefepime may offer a potential treatment option for patients with serious GN bacterial infections. This study aimed to evaluate the in vitro activity of a novel combination of cefepime-taniborbactam and comparators against recent Gram-negative clinical isolates from PWC. Recent GN clinical isolates from PWC were tested against cefepime-taniborbactam and comparators. Clinical and laboratory Standards Institute (CLSI) approved broth microdilution method was used. Appropriate ATCC controls were included. MIC90, and percent of susceptibility calculations were made using FDA breakpoints when available. We tested 100 GN isolates and further testing is ongoing. Cefepime-taniborbactam and comparators antibiotics susceptibility percentage (S: %), and MIC90 are shown in the table below. Cefepime-taniborbactam demonstrated highly potent activity against all of tested Enterobacterales including extended spectrum Beta-lactamase (ESBL), and carbapenem-resistant Enterobacterales (CRE) as well as against P. aeruginosa and Stenotrophomonas maltophilia. At a provisional breakpoint of 16/4 mg/L, cefepime-taniborbactam showed highest activity against all tested isolates when compared to cefepime and other comparators, including activity against ESBL, CRE, MDR P. aeruginosa and S. maltophilia. Our data demonstrate that cefepime-taniborbactam has promising activity against clinically significant multidrug-resistant (MDR) GN bacterial pathogens isolated from PWC and it showed high activity compared to other commonly used broad spectrum antimicrobial agents. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License

  • Open Access

    2124. Novel Polygalacturonic and Caprylic Acid (PG+CAP) Antimicrobial Wound Ointment Effectiveness in Eradicating C. auris Biofilms In Vitro

    by Y Lan Truong, Bahgat Z Gerges, Joel Rosenblatt, Issam I Raad

    Candida auris (CA) is a multidrug-resistant fungal pathogen of increasing concern and has caused infection outbreaks in hospitals as a result of nosocomial transmission. CA has caused both invasive bloodstream and wound infections with significant morbidity and mortality. Recently, a novel polygalacturonic and caprylic acid (PG+CAP) antimicrobial wound ointment was highly effective in healing microbially contaminated chronic wounds in a pilot prospective randomized clinical trial when compared to MediHoney. In order to better combat CA wound infections, here we assessed the effectiveness of PG+CAP and MediHoney wound ointments in eradicating mature CA biofilms in vitro. A well-established biofilm eradication model was used to quantify antimicrobial efficacy. Forty-eight-hour biofilm of two different strains of CA (AR0381 and AR0382) were formed separately on silicone discs and then exposed to PG+CAP or MediHoney wound ointment for two hours. The silicone discs were sonicated in neutralizer, then serially diluted, plated and counted to enumerate viable colonies remaining following exposure to the ointments. Positive controls were discs that had no wound ointment treatment. Both ointments fully eradicated biofilm for CA strain AR0381. PG+CAP fully eradicated AR0382 biofilm (greater than 5-log reduction) but MediHoney achieved less than a 3-log reduction against AR0382. The difference between PG+CAP and MediHoney for AR0382 was significant (p = 0.02). These results suggest PG+CAP might be a promising ointment for use in treating CA wound infections and merits further study. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License

  • Open Access

    Comparative Effectiveness and Persistence of Antimicrobial Durability in Dry and Wet States of a Novel Antimicrobial Surface Disinfectant

    by Bahgat Gerges, Joel Rosenblatt, Ying Jiang, Issam Raad

    Aims: We evaluated a novel disinfectant (VR) and seven comparators (disinfectants A–G) against resistant pathogens common in healthcare settings. Methods and Results: VR at different dilutions, along with commercial disinfectants A–G, was tested against surrogate viruses, and resistant bacterial and fungal pathogens. Surrogate viruses had an initial concentration of ~1 × 108 mL−1, and bacterial and fungal isolates had an initial concentration of ~1 × 106 mL−1 on Siliconee surfaces. After the application of VR or a comparator disinfectant, surfaces were tested for the reduction in microbial loads after 30 s and 5 min wet exposures, and after a 24 h dry residue exposure. Sterile deionized water was used as a control. The VR at a concentration of 4.68% was superior to all comparator disinfectants against most pathogens in wet and dry testing. The VR at 7.8% concentration showed the highest pathogen-reduction rate among all comparator disinfectants when tested against all pathogens. Conclusions: Overall, the novel VR disinfectant was the most effective disinfectant in both wet and dry residue states against the range of tested pathogens. Significance and Impact of the Study: VR is a broadly effective disinfectant combination for use in high-risk settings, particularly those in which intervals between applications of disinfectant can be lengthy or inconsistent.


  • Erratum for Reitzel et al., “Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms”

    by Ruth A. Reitzel, Joel Rosenblatt, Bahgat Z. Gerges, Nylev Vargas-Cruz, Issam I. Raad

    Volume 64, no. 4, e02146-19, 2020, https://doi.org/10.1128/AAC.02146-19. This article was published on 24 March 2020 but required the following additional changes, which were made on 20 October 2021.